First human implant of CARMAT’s total artificial heart

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

CARMAT announces the first human implant of its total artificial heart in the US – implant was performed at Duke University Hospital, one of the US’s largest cardiology centres.

CARMAT has announced the first implantation of its bioprosthetic artificial heart, Aeson®, in the US within the framework of the Early Feasibility Study (EFS).

Longevity.Technology: CARMAT is the designer and developer of what it claims is the world’s most advanced total artificial heart; the company is aiming to fulfil an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure. Affecting, both sides of the heart, biventricular heart failure can cause symptoms of both right-sided and left-sided heart failure, and limits both lifespan and quality of life.

Heart disease is the world’s leading cause of death; being able to replace failing hearts could revolutionise lifespan and massively reduce the healthcare burden. Perhaps it could even propel us on our journey towards longevity escape velocity, the point where life expectancy will continually be extended longer than the time that is passing.

Aeson is composed of an implantable bioprosthesis and a portable external power supply system, to which it is continuously connected.

By pursuing the development of its total artificial heart, CARMAT aims to eventually provide a response to the major public health issue associated with chronic and acute heart failure and overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

CARMAT

Aeson is the result of combining two types of expertise: the medical expertise of Professor Carpentier, known for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, a world aerospace leader.

Physiologic heart replacement therapy

Due to its highly-biocompatible materials, self-regulation system and its pulsatile nature, the CARMAT total artificial heart could, assuming a successful clinical development, potentially save the lives of thousands of patients each year with no risk of rejection and with an enhanced quality of life.

Aeson has the backing of the European Commission; CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance: a total of €33 million.

The implant procedure was performed by a team led by Dr Jacob Schroder and Dr Carmelo Milano, heart surgeons at Duke University Hospital, in Durham (North Carolina). Duke University Hospital has a solid cardiology and heart surgery research track record, and it is the first US hospital to implant Aeson within the framework of the EFS. Three additional US centres are fully trained and are currently screening patients for the study.

In accordance with the study protocol approved by the FDA, 10 transplant-eligible patients are expected to be enrolled in this trial. The primary study endpoint is patient survival at 180 days post-implant or a successful cardiac transplantation within 180 days post-implant. It is a staged study with a progress report of the first three patients after 60 days, before the enrolment of the next seven patients.

Dr Milano, who is also principal investigator of the study, said: “We are encouraged that our patient is doing so well after the procedure Monday … As we evaluate this device, we are both excited and hopeful that patients who otherwise have few to no options could have a lifeline [1].”

Stéphane Piat, Chief Executive Officer of CARMAT, added: “We are honored that our device is implanted at Duke University Hospital, which is recognized throughout the United States for its quality of care and research. I would like to congratulate the teams at the hospital, as well as our technical and medical staff, on this exceptional milestone for both patients and our company. I am also very pleased that, despite the procedures hardened by the Covid-19 situation, three other centers are now fully trained and ready to join our first US clinical study that will be instrumental to our development in the world’s largest medical device market [1].”

[1] https://www.carmatsa.com/en/news/carmat-announces-first-human-implant-total-artificial-heart-united-states/

Images courtesy of CARMAT
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...

A new approach to reversing tissue aging

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale...

Ovarian aging – your questions answered

Ovarian longevity and the significance of ovarian aging is poorly understood – our video aims to change that. Join our Scientific Editor Daragh Campbell as...

Learning lessons from clinical trial failure

Metabesity 2021: Joan Mannick talks longevity scientific breakthroughs, healthspan endpoints, her new role at Life Biosciences, and what can be learned from resTORbio’s clinical...